Manni Kantipudi
Aragen Life Sciences CEO Manni Kantipudi wins 'CEO of the Year Award' at the global CPHI Pharma Award 2022 held in Germany
New Delhi: Aragen Life Sciences, a leading research and development services outsourcing partner to global pharmaceutical firms, has announced that its CEO, Manni Kantipudi, has won the prestigious ‘CEO of the Year’ Award at the CPHI Pharma Awards 2022 held in Messe Frankfurt, Germany.
Manni was recognized for his dynamic leadership, his vision to create a sustainable organization, and his ability to lead the Aragen team toward a common goal by bringing together their collective strengths and capabilities.
The CPHI Pharma Awards celebrates the brightest individuals and companies with the winners selected for their contribution to the field of pharma drug delivery and sustainable growth strategies through innovation in products.
The recognition also showcases world-class technologies and solutions for drug development and clinical research.
Under Manni’s leadership, Aragen has evolved to be a global contract service provider for small molecules and biologics. It has continuously expanded its service portfolio, made strategic acquisitions in India and the US, certified by GPTW three times in a row, achieved Silver rating for its sustainability initiatives by EcoVadis and is a part of various global sustainability initiatives, such as SBTi, PSIC, UNGC and many others.
Manni Kantipudi was chosen from a shortlist of six candidates across the globe for demonstrating keen ability to engage staff and customers, while remaining committed to the development of the global contract research and manufacturing industry.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
